Рынок назальных спреев Азиатско-Тихоокеанского региона – тенденции отрасли и прогноз до 2030 года

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Рынок назальных спреев Азиатско-Тихоокеанского региона – тенденции отрасли и прогноз до 2030 года

  • Pharmaceutical
  • Published Report
  • Apr 2023
  • Asia-Pacific
  • 350 Pages
  • Количество таблиц: 110
  • Количество рисунков: 47

Asia Pacific Nasal Spray Market

Размер рынка в млрд долларов США

CAGR :  % Diagram

Diagram Прогнозируемый период
2023 –2030
Diagram Размер рынка (базовый год)
МИЛЛИОН ДОЛЛАРОВ США
Diagram Размер рынка (прогнозируемый год)
USD 6,248.16
Diagram CAGR
%
Diagram Основные игроки рынка
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Рынок назальных спреев в Азиатско-Тихоокеанском регионе по типу продукции (назальный спрей для устранения заложенности носа, стероидный назальный спрей, назальный спрей на основе солевого раствора/физиологического раствора и другие), конструкции контейнера (флаконы с помпой и баллончики под давлением), лекарственной форме (многодозовая, единичная/однократная доза и двухдозовая), терапевтическому классу (антигистаминный препарат, назальный стероид, ингибитор тучных клеток и антихолинергический препарат), применению (заложенность носа, аллергический и неаллергический ринит, расстройства центральной нервной системы, вакцинация и другие), рецепту/доступности (без рецепта и по рецепту), конечному пользователю (учреждения по уходу на дому, больницы, клиники и общественное здравоохранение) — тенденции отрасли и прогноз до 2030 года.

Рынок назальных спреев Азиатско-Тихоокеанского региона

Анализ и информация о рынке назальных спреев в Азиатско-Тихоокеанском регионе

Аллергический ринит — это серьезная проблема со здоровьем, которая беспокоит более 500 миллионов человек в мире. Он имеет такие симптомы, как заложенность носа, храп, постназальный синдром и кашель, снижение обоняния, головную боль и другие в течение месяцев или лет почти у половины пациентов на земле. Эти симптомы также могут влиять на качество жизни пациентов.

Рынок назальных спреев Азиатско-Тихоокеанского регионаРынок назальных спреев Азиатско-Тихоокеанского региона

Назальный спрей — это устройство, широко используемое в качестве системы для назальной доставки лекарств для лечения основных аллергических проблем, таких как заложенность носа, инфекции, зуд или слезотечение, насморк, заложенность груди, кашель, хрипы, затрудненное дыхание, поверхностное дыхание и другие. Некоторые другие заболевания, которые также включают носовые полипы, воспалительные заболевания кишечника, проблемы с почками и другие. Введение лекарств или препаратов через нос в дозированной форме с помощью спрея — это неинвазивный метод, который обеспечивает быстрое действие препарата в организме пациентов. Назальный спрей является одним из самых экономически эффективных, не требует вторжения, прост в использовании и самостоятельном введении и имеет высокую степень соблюдения пациентом режима лечения. Поэтому назальная доставка лекарств является одним из популярных способов введения лекарств в последнее время и имеет большие возможности для роста.

Назальные спреи доступны на рынке как безрецептурные (OTC) или рецептурные препараты для лечения заболеваний носа, таких как назальная аллергия, заложенный или заложенный нос, хронический синусит, аллергический ринит и другие проблемы, связанные с носом. Эти спреи доступны на рынке в виде помпы или баллончика.

По данным исследования рынка Data Bridge, ожидается, что к 2030 году объем рынка назальных спреев в Азиатско-Тихоокеанском регионе достигнет 6 248,16 млн долларов США, а среднегодовой темп роста в прогнозируемый период составит 7,1%.

Отчет Метрика

Подробности

Прогнозируемый период

2023-2030

Базовый год

2022

Исторический год

2021 (можно настроить на 2015-2020)

Количественные единицы

Доход в миллионах, объемы в единицах и цены в долларах США

Охваченные сегменты

Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care)

Countries Covered

China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and Rest of Asia-Pacific

Market Players Covered

EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD, and Aishwarya Group among others

Market Definition

Nasal sprays are devices that help in the delivery of the drug through the nose in the nasal cavity to treat allergies and other problems related to brain inflammation, diabetes, dental problems, and the central nervous system. Allergy is a condition in which the immune system of the body reacts abnormally to a foreign substance. Nasal spray drug products consist of therapeutically active ingredients or drug substances in the form of solution or suspension of excipients.

There are different types of nasal spray available in the market, such as decongestion nasal spray, saline nasal spray, and steroid nasal spray. Decongestants are devices with drugs for the treatment of nasal congestion and provide short-term relief from a blocked nose. The decongestion nasal spray consists of drugs that open up the airways of the nasal part and helps in the breathing process.

During the cold and dry winter season, saline nasal sprays are used to avoid problems related to a stuffy nose. These devices are used to treat sinusitis, nasal crusting, and thin secretions of liquid from the nose, which are formed due to bacterial infection and lead to the dryness of the nasal area. This device helps in cleaning the nasal passage and mucus present in that area due to cold.

Asia-Pacific Nasal Spray Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVER

  • Increase in Infection and Allergic Cases

Allergy is a condition that makes the immune system weaken, and the immune system reacts abnormally to a foreign substance. Allergies have many forms, such as Allergic Rhinitis (AR), and this affects nearly 40 to 50 million people in the U.S. Some allergies may interfere with day-to-day activities and the quality of life.

Due to the increase in population, urbanization, and industrialization has increased tremendously, which has led to a rise in allergen. This allergen is responsible for allergies or infectious diseases in many people.

Thus, the rise in the prevalence of allergic diseases such as AR has led to an increase in the demand for nasal sprays, which is expected to drive market growth in the coming years.

RESTRAINT

  • Adverse Effects of Using Nasal Sprays

Many people opt for nasal sprays in order to get relief from a runny and stuffy nose, but using a nasal spray for a longer period of time causes several side effects. Steroid nasal sprays, also called corticosteroid nasal sprays, are anti-inflammatory medicines that are sprayed into the nose. They can be used to treat a range of conditions, including hay fever, sinusitis, non-allergic rhinitis, and nasal polyps. Some steroid nasal sprays are available to buy from pharmacies and shops, while others are only available on prescription.

Using nasal sprays for a prolonged period of time can lead to bleeding from the nose and even headaches. Some may experience other side effects, such as addiction or even congestion.

If one is taking a high dose for a long time, there is also a small chance one could get some of the side effects of steroid tablets, such as increased appetite, mood changes, and difficulty sleeping.

Thus, the adverse effects of nasal sprays are expected to restrain the market growth.

OPPORTUNITY

  • Expanding Therapeutic Applications for Nasal Sprays

Intranasal administration provides various useful options for the local and systemic delivery of diverse therapeutic agents for the treatment of problems such as allergies, respiratory diseases, and many others.

A nasal spray is one of the recently developed products, such as OptiNose and ViaNase, that helps to enable the targeting of formulations to a specific area of the site in the nasal cavity in humans.

Nasal therapy has been known as a form of treatment in Indian medicine for decades. It is also called “NASAYA KARMA” in Ayurvedic systems in Indian medicine.

The nasal spray consists of one or more than one therapeutically active ingredients in the form of suspension or solution in a non-pressurized dispenser. The most common allergy is AR.

Apart from respiratory problems, there are other therapeutic areas such as orthopedic, renal, and many other areas, where the nasal spray is playing important role in treating and curing such problems. In the future, other treatments may be developed that can help in the treatment of other problems easily.

CHALLENGE

  • Regulatory Hurdles

Nasal drug delivery can be evaluated by many regulatory agencies, such as the U.S. FDA and the European Medicines Agency (EMA). These agencies provide a set of guidelines and regulations for any product before it is launched in the market. They allow performing various in vitro test methods for determining the characterization of nasal drug products and that should come in an acceptable range as given by such regulatory bodies.

Nasal spray can be designed as per the dose requirement of drug substances for patients suffering from nasal or any other issues. Some aspects of nasal sprays may be exceptional in the case of formulation, manufacturing, container closure system, stability, controls of critical steps, intermediates, and drug products. These aspects should be measured carefully while developing a program of nasal spray. Because of these changes ability of the product to treat patients may get affected.

Strict rules and regulations for the product for nasal spray manufacturing are more challenging for the manufacturer to get approval from regulatory agencies. The spray characteristics can be influenced by the design of the device, and by the handling of the device. Performing such tests to get the perfect result, that is, an acceptable range as given by the regulatory body, is more challenging in nasal spray manufacturing.

Post-COVID-19 Impact Analysis on the Asia-Pacific Nasal Spray Market

COVID-19 had a significant impact on the generic drug market for inhalation and nasal spray, as one of the main symptoms associated with COVID-19 is shortness of breath. The demand for inhalation and nasal spray increased during the pandemic.

For instance,

  • According to a MedComm journal article published in 2021, nasal sprays demonstrated the ability to be an effective COVID-19 treatment and vaccine option

Spray formulations that may inactivate SARS-CoV-2 or restrict its entry into cells were thought to be beneficial in preventing viral spread to the lungs or surrounding people. Relaxed lockdowns and the resumption of healthcare practices are expected to accelerate market growth in the post-pandemic era. COVID-19 patients are still experiencing long-term side effects such as shortness of breath.

Recent Developments

  • In January 2023, Viatris Inc. (NASDAQ: VTRS), a Asia-Pacific healthcare company, today announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. This acquisition would help the company in its business expansion.
  • In March 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd, announced the launch of additional strengths for the generic version of Revlimid1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the U.S. This product launch would help the company in its product portfolio expansion.

Asia-Pacific Nasal Spray Market Scope

The Asia-Pacific nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

PRODUCT TYPE

  • DECONGESTION NASAL SPRAY
  • STEROID NASAL SPRAY
  • SALT WATER SOLUTION/ SALINE NASAL SPRAY
  • OTHERS

On the basis of product type, the market is segmented into decongestion nasal spray, salt water solution/saline nasal spray, steroid nasal spray, and others.

CONTAINER DESIGN

  • PUMP BOTTLES
  • PRESSURIZED CANISTERS

On the basis of container design, the market is segmented into pressurized canisters and pump bottles.

DOSAGE FORM

  • MULTI DOSE
  • UNIT/SINGLE DOSE
  • BI DOSE

On the basis of dosage form, the market is segmented into unit/single dose, bi dose, and multi dose.

THERAPEUTIC CLASS

  • ANTIHISTAMINE
  • NASAL STEROIDS
  • MAST CELL INHIBITOR
  • ANTICHOLINERGIC

On the basis of therapeutic class, the market is segmented into antihistamine, nasal steroids, mast cell inhibitor, and anticholinergic.

APPLICATION

  • NASAL CONGESTION
  • ALLERGIC AND NON-ALLERGIC RHINITIS
  • CENTRAL NERVOUS SYSTEM DISORDERS
  • VACCINATION
  • OTHERS

On the basis of application, the market is segmented into nasal congestion, allergic and non-allergic rhinitis, central nervous system disorders, vaccination, and others.

PRESCRIPTION/AVAILABILITY

  • OVER THE COUNTER
  • PRESCRIBED

On the basis of prescription/availability, the market is segmented into over the counter and prescribed.

END USER

  • HOME CARE SETTINGS
  • HOSPITALS
  • CLINICS
  • COMMUNITY HEALTH CARE

On the basis of end user, the market is segmented into home care settings, hospitals, clinics, and community health care.

Рынок назальных спреев

Asia-Pacific Nasal Spray Market Regional Analysis/Insights

The Asia-Pacific nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user.

The countries covered in this market report are China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and the rest of Asia-Pacific.

In 2023, China is dominating the Asia-Pacific nasal spray market due to increasing customer inclinations toward nasal spray.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании на внутреннем рынке, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые продажи, заменяющие продажи, демографические данные страны, нормативные акты и импортно-экспортные тарифы, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по странам учитываются наличие и доступность брендов Азиатско-Тихоокеанского региона и их проблемы, связанные с большой или малой конкуренцией со стороны местных и отечественных брендов, а также влияние каналов продаж.

Анализ конкурентной среды и доли рынка назальных спреев в Азиатско-Тихоокеанском регионе

Конкурентная среда рынка назальных спреев в Азиатско-Тихоокеанском регионе содержит сведения о конкурентах. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в НИОКР, новых рыночных инициативах, производственных площадках и объектах, сильных и слабых сторонах компании, запуске продукта, одобрении продукта, широте и широте продукта, доминировании приложений и жизненно важной кривой типа продукта. Приведенные выше данные относятся только к фокусу компании на рынке.

Некоторые из основных игроков, работающих на рынке назальных спреев Азиатско-Тихоокеанского региона, включают EMERGENT, Cipla Inc., Sandoz International GmbH (часть Novartis), Aytu Health (дочерняя компания Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc. (дочерняя компания Teva Pharmaceutical Industries Ltd), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD и Aishwarya Group и другие.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES MODEL

4.2 PESTEL ANALYSIS

5 INDUSTRY INSIGHTS: ASIA PACIFIC NASAL SPRAY MARKET

5.1 INDUSTRY INSIGHTS

6 REGULATIONS: ASIA PACIFIC NASAL SPRAY MARKET

6.1 REGULATORY SCENARIO IN INDIA

6.2 REGULATORY SCENARIO IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES

7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA

7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY

7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY

7.2 RESTRAINTS

7.2.1 PRODUCT RECALLS

7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS

7.3 OPPORTUNITIES

7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY

7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS

7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS

7.4 CHALLENGES

7.4.1 REGULATORY HURDLES

7.4.2 ADDICTION TO NASAL SPRAY

8 ASIA PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 DECONGESTION NASAL SPRAY

8.3 STEROID NASAL SPRAY

8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY

8.5 OTHERS

9 ASIA PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN

9.1 OVERVIEW

9.2 PUMP BOTTLES

9.3 PRESSURIZED CANISTERS

10 ASIA PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 MULTI DOSE

10.3 UNIT/SINGLE DOSE

10.4 BI DOSE

11 ASIA PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS

11.1 OVERVIEW

11.2 ANTIHISTAMINE

11.3 NASAL STEROIDS

11.4 MAST CELL INHIBITOR

11.5 ANTICHOLINERGIC

12 ASIA PACIFIC NASAL SPRAY MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 NASAL CONGESTION

12.3 ALLERGIC AND NON-ALLERGIC RHINITIS

12.4 CENTRAL NERVOUS SYSTEM DISORDERS

12.5 VACCINATION

12.6 OTHERS

13 ASIA PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY

13.1 OVERVIEW

13.2 PRESCRIBED

13.3 OVER THE COUNTER

14 ASIA PACIFIC NASAL SPRAY MARKET, BY END USER

14.1 OVERVIEW

14.2 HOME CARE SETTINGS

14.3 HOSPITALS

14.4 CLINICS

14.5 COMMUNITY HEALTH CARE

15 ASIA PACIFIC NASAL SPRAY MARKET, BY REGION

15.1 ASIA-PACIFIC

15.1.1 CHINA

15.1.2 JAPAN

15.1.3 INDIA

15.1.4 AUSTRALIA

15.1.5 SOUTH KOREA

15.1.6 MALAYSIA

15.1.7 THAILAND

15.1.8 SINGAPORE

15.1.9 INDONESIA

15.1.10 PHILIPPINES

15.1.11 REST OF ASIA-PACIFIC

16 ASIA PACIFIC NASAL SPRAY MARKET, COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 GLAXOSMITHKLINE PLC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 EMERGENT

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS)

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 CATALENT, INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENTS

18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.)

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENTS

18.7 AISHWARYA GROUP

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENTS

18.8 ASSERTIO THERAPEUTICS, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENT

18.9 AURENA LABORATORIES.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENTS

18.1 BAYER AG

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 COMPANY SHARE ANALYSIS

18.10.4 PRODUCT PORTFOLIO

18.10.5 RECENT DEVELOPMENTS

18.11 CIPLA INC.

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 J PHARMACEUTICALS.

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENTS

18.13 LEEFORD HEALTHCARE LTD

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENTS

18.14 ST. RENATUS.

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENTS

18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENTS

18.16 ULTRATECH INDIA LIMITED

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENTS

18.17 VIATRIS INC.

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 COMPANY SHARE ANALYSIS

18.17.4 PRODUCT PORTFOLIO

18.17.5 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

Список таблиц

TABLE 1 ASIA PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 ASIA PACIFIC DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 ASIA PACIFIC STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 ASIA PACIFIC SALT WATER SOLUTION/SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 ASIA PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 ASIA PACIFIC PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 ASIA PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 10 ASIA PACIFIC MULTI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 ASIA PACIFIC UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 ASIA PACIFIC BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 ASIA PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 14 ASIA PACIFIC ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 ASIA PACIFIC NASAL STEROIDS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 ASIA PACIFIC MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 ASIA PACIFIC ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA PACIFIC NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 19 ASIA PACIFIC NASAL CONGESTION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 ASIA PACIFIC ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 ASIA PACIFIC CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA PACIFIC VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 ASIA PACIFIC OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 ASIA PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 25 ASIA PACIFIC PRESCRIBED IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA PACIFIC OVER THE COUNTER IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 ASIA PACIFIC NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 28 ASIA PACIFIC HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 ASIA PACIFIC HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA PACIFIC CLINICS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 ASIA PACIFIC COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA-PACIFIC NASAL SPRAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 33 ASIA-PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 34 ASIA-PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 35 ASIA-PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 36 ASIA-PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 38 ASIA-PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 40 CHINA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 41 CHINA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 42 CHINA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 43 CHINA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 44 CHINA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 45 CHINA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 46 CHINA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 47 JAPAN NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 48 JAPAN NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 49 JAPAN NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 50 JAPAN NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 51 JAPAN NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 52 JAPAN NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 53 JAPAN NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 54 INDIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 INDIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 56 INDIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 57 INDIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 58 INDIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 59 INDIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 60 INDIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 61 AUSTRALIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 62 AUSTRALIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 63 AUSTRALIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 64 AUSTRALIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 65 AUSTRALIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 66 AUSTRALIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 67 AUSTRALIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 68 SOUTH KOREA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 69 SOUTH KOREA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 70 SOUTH KOREA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 71 SOUTH KOREA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 72 SOUTH KOREA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 73 SOUTH KOREA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 74 SOUTH KOREA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 75 MALAYSIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 76 MALAYSIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 77 MALAYSIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 78 MALAYSIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 79 MALAYSIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 80 MALAYSIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 81 MALAYSIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 82 THAILAND NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 83 THAILAND NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 84 THAILAND NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 85 THAILAND NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 86 THAILAND NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 87 THAILAND NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 88 THAILAND NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 89 SINGAPORE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 SINGAPORE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 91 SINGAPORE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 92 SINGAPORE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 93 SINGAPORE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 94 SINGAPORE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 95 SINGAPORE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 96 INDONESIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 INDONESIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 98 INDONESIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 99 INDONESIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 100 INDONESIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 101 INDONESIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 102 INDONESIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 103 PHILIPPINES NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 104 PHILIPPINES NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 105 PHILIPPINES NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 106 PHILIPPINES NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 107 PHILIPPINES NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 108 PHILIPPINES NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 109 PHILIPPINES NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 110 REST OF ASIA-PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

Список рисунков

FIGURE 1 ASIA PACIFIC NASAL SPRAY MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC NASAL SPRAY MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC NASAL SPRAY MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC NASAL SPRAY MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC NASAL SPRAY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC NASAL SPRAY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC NASAL SPRAY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC NASAL SPRAY MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 ASIA PACIFIC NASAL SPRAY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC NASAL SPRAY MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN INFECTION AND ALLERGIC CASES IS EXPECTED TO DRIVE THE ASIA PACIFIC NASAL SPRAY MARKET IN THE FORECAST PERIOD

FIGURE 12 THE DECONGESTION NASAL SPRAY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC NASAL SPRAY MARKET IN 2023 AND 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC NASAL SPRAY MARKET

FIGURE 14 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, 2022

FIGURE 15 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 16 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 17 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 18 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2022

FIGURE 19 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2023-2030 (USD MILLION)

FIGURE 20 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, CAGR (2023-2030)

FIGURE 21 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, 2022

FIGURE 23 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, 2023-2030 (USD MILLION)

FIGURE 24 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, CAGR (2023-2030)

FIGURE 25 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2022

FIGURE 27 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION)

FIGURE 28 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030)

FIGURE 29 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE

FIGURE 30 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, 2022

FIGURE 31 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 32 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 33 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 34 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2022

FIGURE 35 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2023-2030 (USD MILLION)

FIGURE 36 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, CAGR (2023-2030)

FIGURE 37 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, LIFELINE CURVE

FIGURE 38 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, 2022

FIGURE 39 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 40 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, CAGR (2023-2030)

FIGURE 41 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, LIFELINE CURVE

FIGURE 42 ASIA-PACIFIC NASAL SPRAY MARKET: SNAPSHOT (2022)

FIGURE 43 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2022)

FIGURE 44 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2023 & 2030)

FIGURE 45 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2022 & 2030)

FIGURE 46 ASIA-PACIFIC NASAL SPRAY MARKET: PRODUCT TYPE (2023-2030)

FIGURE 47 ASIA PACIFIC NASAL SPRAY MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

The Asia-Pacific Nasal Spray Market is projected to grow at a CAGR of 7.1% during the forecast period by 2030.
The future market value of the Asia-Pacific Nasal Spray Market is expected to reach USD 6,248.16 million by 2030.
The major players in the Asia-Pacific Nasal Spray Market are EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., etc.
The countries covered in the Asia-Pacific Nasal Spray Market are China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and Rest of Asia-Pacific.